GlassScriptPhysician profile
Sydney Welt
NPI 1740256809
$4,335.42
in general payments reported to CMS, 2019-2025
29 companies · $561 in 2025
The $561 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,302 · 2020: $644 · 2021: $363 · 2022: $683 · 2023: $635 · 2024: $147 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,208 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,208.12 |
| Education | $135.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $548.73 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $466.44 | 2019-2023 | Tagrisso, Imfinzi |
| Novartis Pharmaceuticals Corporation | $401.26 | 2019-2025 | |
| Lilly USA, LLC | $335.12 | 2021-2023 | Verzenio |
| Daiichi Sankyo INC. | $320.66 | 2019-2023 | Enhertu |
| Amgen INC. | $302.51 | 2019-2020 | |
| Novocure Gmbh | $250.00 | 2022 | |
| Glaxosmithkline, LLC. | $177.74 | 2020-2025 | Jemperli |
| Genentech USA, INC. | $171.77 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $169.32 | 2019-2023 | Keytruda |
| Janssen Biotech, INC. | $140.67 | 2019-2024 | Darzalex, Tecvayli |
| Beone Medicines USA, INC. | $128.75 | 2025 | Brukinsa |
| Gilead Sciences, INC. | $125.00 | 2023 | Trodelvy |
| Exelixis INC. | $125.00 | 2025 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $116.66 | 2025 | Libtayo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $80.05 | 2019-2020 | |
| Pfizer INC. | $76.66 | 2019-2025 | |
| Incyte Corporation | $75.38 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.92 | 2019-2020 | |
| Genentech, INC. | $39.95 | 2019 | |
| Alexion Pharmaceuticals, INC. | $35.23 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $31.09 | 2019-2020 | |
| Taiho Oncology, INC. | $29.68 | 2020 | |
| Secura Bio, INC. | $29.47 | 2020 | |
| Celgene Corporation | $20.70 | 2019 | |
| Caris Mpi, INC. | $19.45 | 2025 | Mi Cancer Seek |
| Seagen INC. | $18.61 | 2020 | |
| Ethicon US, LLC | $16.73 | 2019 | |
| Dova Pharmaceuticals | $15.87 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sydney Welt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.